For example, some drugs have been designed to simultaneously inhibit EGFR and ALK, two mutant kinases commonly found in NSCLC, as a way to overcome the resistance of tumor cells to single-target EGFR inhibitors [170]. Here, EGFR is linked to non-small cell lung carcinoma.